2023 Q4 Form 10-Q Financial Statement

#000149315223040442 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $2.152M $1.930M
YoY Change -100.0% 11.48% 29.32%
Cost Of Revenue $0.00 $1.477M $1.491M
YoY Change -100.0% -0.94% 49.48%
Gross Profit $0.00 $675.1K $439.6K
YoY Change -100.0% 53.58% -11.26%
Gross Profit Margin 31.38% 22.77%
Selling, General & Admin $1.775M $867.9K $861.6K
YoY Change 65.33% 0.72% 114.2%
% of Gross Profit 128.55% 196.01%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization -$318.1K $19.18K $18.21K
YoY Change -1738.9% 5.35% 21.06%
% of Gross Profit 2.84% 4.14%
Operating Expenses $1.775M $867.9K $861.6K
YoY Change 65.33% 0.72% 114.2%
Operating Profit -$1.775M -$192.7K -$422.0K
YoY Change 221.2% -54.33% -553.37%
Interest Expense $56.45K $29.55K $20.28K
YoY Change -136.9% 45.7% -310.4%
% of Operating Profit
Other Income/Expense, Net $1.290K -$16.86K $49.32K
YoY Change -134.19% 1123.87%
Pretax Income $3.088M -$209.6K -$372.7K
YoY Change -537.58% -43.77% -529.3%
Income Tax $8.160K $800.00
% Of Pretax Income 0.26%
Net Earnings $3.158M -$173.2K -$238.8K
YoY Change -805.76% -27.49% 6944.96%
Net Earnings / Revenue -8.05% -12.37%
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share $0.12 -$0.01 -$10.41K
COMMON SHARES
Basic Shares Outstanding 22.69M shares 22.94M shares 22.94M shares
Diluted Shares Outstanding 22.75M shares 22.94M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.079M $476.4K $1.539M
YoY Change 289.74% -69.04% 269.5%
Cash & Equivalents $2.431M $470.7K $1.437M
Short-Term Investments $647.4K $5.610K $101.5K
Other Short-Term Assets $6.510K $98.80K $87.17K
YoY Change -90.14% 13.34% 242.65%
Inventory
Prepaid Expenses $6.508K $98.80K $87.17K
Receivables $1.800K $730.2K $604.7K
Other Receivables $15.00K $20.37K $330.6K
Total Short-Term Assets $4.102M $1.326M $2.566M
YoY Change 138.48% -48.34% 111.29%
LONG-TERM ASSETS
Property, Plant & Equipment $1.591K $181.9K $150.4K
YoY Change -98.92% 20.92% -79.9%
Goodwill $0.00 $1.426M $1.426M
YoY Change -100.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $343.3K $351.4K $502.4K
YoY Change -21.14% -30.05% 6.13%
Other Assets $343.3K $3.662M $3.124M
YoY Change -89.02% 17.21% 718.93%
Total Long-Term Assets $344.9K $3.844M $3.275M
YoY Change -89.47% 17.38% -1.78%
TOTAL ASSETS
Total Short-Term Assets $4.102M $1.326M $2.566M
Total Long-Term Assets $344.9K $3.844M $3.275M
Total Assets $4.447M $5.170M $5.841M
YoY Change -10.95% -11.49% 28.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.152K $51.63K $29.73K
YoY Change -90.18% 73.66% 19.94%
Accrued Expenses $91.46K $602.5K $1.022M
YoY Change -86.12% -41.06% 174.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $50.55K $0.00
YoY Change
Long-Term Debt Due $29.24K
YoY Change -82.02%
Total Short-Term Liabilities $94.61K $1.198M $1.572M
YoY Change -90.71% -23.79% 166.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $62.03K
YoY Change -100.0% -92.83%
Other Long-Term Liabilities $436.5K $1.429M $1.147M
YoY Change -70.13% 24.56% 0.67%
Total Long-Term Liabilities $436.5K $2.551M $1.871M
YoY Change -80.6% 36.35% -6.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $94.61K $1.198M $1.572M
Total Long-Term Liabilities $436.5K $2.551M $1.871M
Total Liabilities $531.1K $3.749M $3.443M
YoY Change -83.75% 8.89% 40.92%
SHAREHOLDERS EQUITY
Retained Earnings -$8.188M -$11.70M -$10.90M
YoY Change -27.83% 7.33%
Common Stock $2.469K $2.269K $2.294K
YoY Change 7.63% -1.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.916M $1.421M $2.398M
YoY Change
Total Liabilities & Shareholders Equity $4.447M $5.170M $5.841M
YoY Change -10.95% -11.49% 28.41%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income $3.158M -$173.2K -$238.8K
YoY Change -805.76% -27.49% 6944.96%
Depreciation, Depletion And Amortization -$318.1K $19.18K $18.21K
YoY Change -1738.9% 5.35% 21.06%
Cash From Operating Activities -$1.976M -$196.6K $943.4K
YoY Change 99.93% -120.84% 4170.48%
INVESTING ACTIVITIES
Capital Expenditures -$83.06K $46.76K -$19.31K
YoY Change -623.05% -342.15% -79.01%
Acquisitions
YoY Change
Other Investing Activities $6.966M $300.00 -$28.97K
YoY Change 1486.44% -101.04% -132.92%
Cash From Investing Activities $7.049M -$46.46K -$48.28K
YoY Change 1565.6% -3.77% 1101.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.113M -122.9K -55.14K
YoY Change 3677.45% 122.96% 38.4%
NET CHANGE
Cash From Operating Activities -1.976M -196.6K 943.4K
Cash From Investing Activities 7.049M -46.46K -48.28K
Cash From Financing Activities -3.113M -122.9K -55.14K
Net Change In Cash 1.961M -366.0K 839.9K
YoY Change -402.85% -143.58% -3958.2%
FREE CASH FLOW
Cash From Operating Activities -$1.976M -$196.6K $943.4K
Capital Expenditures -$83.06K $46.76K -$19.31K
Free Cash Flow -$1.893M -$243.4K $962.7K
YoY Change 88.49% -125.28% 743.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
MNTR Payments To Proceeds From Investment Securities
PaymentsToProceedsFromInvestmentSecurities
usd
MNTR Decrease In Accrued Investment Interest Income
DecreaseInAccruedInvestmentInterestIncome
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001599117
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 MNTR Employee Retention Credits
EmployeeRetentionCredits
usd
CY2022Q3 MNTR Employee Retention Credits
EmployeeRetentionCredits
usd
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
usd
MNTR Down Payment On Right Of Use Assets
DownPaymentOnRightOfUseAssets
usd
MNTR Proceeds From Warrants Converted To Common Stock
ProceedsFromWarrantsConvertedToCommonStock
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
MNTR Property And Equipment Acquired Via Longterm Debt
PropertyAndEquipmentAcquiredViaLongtermDebt
usd
CY2023Q3 MNTR Investment In Account Receivable Current
InvestmentInAccountReceivableCurrent
usd
CY2022Q4 MNTR Investment In Account Receivable Current
InvestmentInAccountReceivableCurrent
usd
CY2023Q3 MNTR Employee Retention Tax Credits
EmployeeRetentionTaxCredits
usd
CY2022Q4 MNTR Employee Retention Tax Credits
EmployeeRetentionTaxCredits
usd
CY2023Q3 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
usd
CY2023Q3 MNTR Operating Lease Cost Included In Cost Of Goods
OperatingLeaseCostIncludedInCostOfGoods
usd
MNTR Operating Lease Cost Included In Cost Of Goods
OperatingLeaseCostIncludedInCostOfGoods
usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2023Q3 MNTR Long Term Debt One
LongTermDebtOne
usd
CY2023Q3 MNTR Long Term Debt Two
LongTermDebtTwo
usd
CY2023Q3 MNTR Long Term Debt Three
LongTermDebtThree
usd
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
usd
CY2023Q3 MNTR Employee Retention Credits
EmployeeRetentionCredits
usd
CY2022Q3 MNTR Employee Retention Credits
EmployeeRetentionCredits
usd
CY2023Q3 us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
usd
CY2022Q3 us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
usd
us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55323
dei Entity Registrant Name
EntityRegistrantName
Mentor Capital, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0395098
dei Entity Address Address Line1
EntityAddressAddressLine1
5964 Campus Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Plano
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75093
dei City Area Code
CityAreaCode
(760)
dei Local Phone Number
LocalPhoneNumber
788-4700
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22686105 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
470732 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
789930 usd
CY2023Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
5614 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
730157 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
633778 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
20374 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
230322 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
98796 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
66000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1325673 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1720030 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
441077 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
355725 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
259199 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
208847 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181878 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
146878 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
323875 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
370164 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1560757 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
895323 usd
CY2023Q3 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
224500 usd
CY2022Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
315309 usd
CY2023Q3 us-gaap Deposit Assets
DepositAssets
22477 usd
CY2022Q4 us-gaap Deposit Assets
DepositAssets
25575 usd
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
104431 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
94431 usd
CY2023Q3 us-gaap Goodwill
Goodwill
1426182 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1426182 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3662222 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3126984 usd
CY2023Q3 us-gaap Assets
Assets
5169773 usd
CY2022Q4 us-gaap Assets
Assets
4993892 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
51632 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32092 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
602529 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658743 usd
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
50545 usd
CY2023Q3 MNTR Economic Injury Disaster Loan Current Portion
EconomicInjuryDisasterLoanCurrentPortion
6235 usd
CY2022Q4 MNTR Economic Injury Disaster Loan Current Portion
EconomicInjuryDisasterLoanCurrentPortion
3191 usd
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
419073 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
232058 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67804 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
62861 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
29011 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1197818 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1017956 usd
CY2023Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1173153 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1153948 usd
CY2023Q3 MNTR Economic Injury Disaster Loan
EconomicInjuryDisasterLoan
51797 usd
CY2022Q4 MNTR Economic Injury Disaster Loan
EconomicInjuryDisasterLoan
157869 usd
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1069810 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
575852 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
256071 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
307303 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
54865 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2550831 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2249837 usd
CY2023Q3 us-gaap Liabilities
Liabilities
3748649 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3267793 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22686105 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22686105 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22941357 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22941357 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2269 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2294 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13078134 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13085993 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11697286 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11345465 usd
CY2023Q3 MNTR Noncontrolling Interest
NoncontrollingInterest
38007 usd
CY2022Q4 MNTR Noncontrolling Interest
NoncontrollingInterest
-16723 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1421124 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1726099 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5169773 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4993892 usd
CY2023Q3 us-gaap Revenues
Revenues
2151811 usd
CY2022Q3 us-gaap Revenues
Revenues
1930299 usd
us-gaap Revenues
Revenues
6432616 usd
us-gaap Revenues
Revenues
5647817 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1476677 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1490712 usd
us-gaap Cost Of Revenue
CostOfRevenue
4151400 usd
us-gaap Cost Of Revenue
CostOfRevenue
3924380 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
675134 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
439587 usd
us-gaap Gross Profit
GrossProfit
2281216 usd
us-gaap Gross Profit
GrossProfit
1723437 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
867863 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
861628 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2537644 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2777865 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-192729 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-422041 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-256428 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1054428 usd
MNTR Employee Retention Credits
EmployeeRetentionCredits
6921 usd
MNTR Employee Retention Credits
EmployeeRetentionCredits
1350161 usd
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
939 usd
CY2022Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
590 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
715 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-39661 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
10730 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12887 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
27564 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
40632 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
29553 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
20283 usd
us-gaap Interest Expense
InterestExpense
76349 usd
us-gaap Interest Expense
InterestExpense
58052 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
56455 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1021 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56128 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14430 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58026 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16863 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49322 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26719 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1407561 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-209592 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-372719 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-283147 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
353133 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13944 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47690 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-209592 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-373519 usd
us-gaap Profit Loss
ProfitLoss
-297091 usd
us-gaap Profit Loss
ProfitLoss
305443 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-36429 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-134695 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
54730 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
329419 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-173163 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-238824 usd
us-gaap Net Income Loss
NetIncomeLoss
-351821 usd
us-gaap Net Income Loss
NetIncomeLoss
-23976 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.008
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.008
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.010
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.010
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.015
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.015
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22749918 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22749918 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22941357 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22941357 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22864781 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22864781 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22941357 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22941357 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1637987 usd
CY2023Q3 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
7271 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-209592 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1421124 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2771985 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-373519 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2398466 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1726099 usd
us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
7884 usd
us-gaap Profit Loss
ProfitLoss
-297091 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1421124 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2078677 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14346 usd
us-gaap Profit Loss
ProfitLoss
305443 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2398466 usd
us-gaap Profit Loss
ProfitLoss
-297091 usd
us-gaap Profit Loss
ProfitLoss
305443 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50352 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51847 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
269470 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
147419 usd
us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
26168 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10198 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
53000 usd
MNTR Amortization Of Discount On Investment In Account Receivable
AmortizationOfDiscountOnInvestmentInAccountReceivable
-27091 usd
MNTR Amortization Of Discount On Investment In Account Receivable
AmortizationOfDiscountOnInvestmentInAccountReceivable
-38754 usd
MNTR Decrease In Accrued Investment Interest Income
DecreaseInAccruedInvestmentInterestIncome
-86325 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
715 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-751 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
41326 usd
MNTR Increase Decrease In Deposit
IncreaseDecreaseInDeposit
3099 usd
MNTR Increase Decrease In Deposit
IncreaseDecreaseInDeposit
-8000 usd
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
-306650 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
106577 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-121730 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-209948 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
370349 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34305 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
46722 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1509 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1161 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
19541 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-11546 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-159243 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
628177 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16308 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
19205 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
19586 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41700 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1160594 usd
MNTR Payments To Proceeds From Investment Securities
PaymentsToProceedsFromInvestmentSecurities
14899 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
85352 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24733 usd
MNTR Down Payment On Right Of Use Assets
DownPaymentOnRightOfUseAssets
42675 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
117900 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
700 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17649 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66708 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50545 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50000 usd
MNTR Proceeds From Warrants Converted To Common Stock
ProceedsFromWarrantsConvertedToCommonStock
14346 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
7884 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
21950 usd
MNTR Payments Of Long Term Debt
PaymentsOfLongTermDebt
83876 usd
MNTR Payments Of Long Term Debt
PaymentsOfLongTermDebt
21085 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
253932 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
131818 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-295147 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-110507 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-319198 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
983379 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
789930 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
453939 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
470732 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1437318 usd
us-gaap Interest Paid Net
InterestPaidNet
32425 usd
us-gaap Interest Paid Net
InterestPaidNet
8736 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11224 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6526 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
934905 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
251896 usd
MNTR Property And Equipment Acquired Via Longterm Debt
PropertyAndEquipmentAcquiredViaLongtermDebt
22480 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_z0VMaecgAUyd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_008"></span>Note 1 - <span id="xdx_829_zfWKGOwaTuX2">Nature of operations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Corporate Structure Overview</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor Capital, Inc. (“Mentor” or “the Company”), reincorporated under the laws of the State of <span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20230101__20230930_zgwemjjpO59e" title="Entity incorporation, state or country code">Delaware</span> in September 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity was originally founded as an investment partnership in Silicon Valley, California, by the current CEO in 1985 and subsequently incorporated under the laws of the State of California on <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230930_zEuk8fIGIIL6" title="Entity incorporation, date of incorporation">July 29, 1994</span>. On September 12, 1996, the Company’s offering statement was qualified pursuant to Regulation A of the Securities Act, and the Company began to trade its shares publicly. On August 21, 1998, the Company filed for voluntary reorganization, and on January 11, 2000, the Company emerged from Chapter 11 reorganization. The Company relocated to San Diego, California, and contracted to provide financial assistance and investment in small businesses. On May 22, 2015, a corporation named Mentor Capital, Inc. (“Mentor Delaware”) was incorporated under the laws of the State of Delaware. A shareholder-approved merger between Mentor and Mentor Delaware was approved by the California and Delaware Secretaries of State and became effective September 24, 2015, thereby establishing Mentor as a Delaware corporation. In September 2020, Mentor relocated its corporate office from San Diego, California, to Plano, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock trades publicly under the trading symbol OTCQB: MNTR.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s broad target industry focus includes energy, facilities operations, and management services with the goal of ensuring increased market opportunities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor has a <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--WasteConsolidatorsIncMember_zP4Lu4p8cDc2" title="Equity method investment, ownership percentage">51</span>% interest in Waste Consolidators, Inc. (“WCI”). WCI was incorporated in Colorado in 1999 and operates in Arizona and Texas. It is a long-standing investment of the Company since 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor’s <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MentorIPLLCMember_zQHn81qZCK99" title="Equity method investment, ownership percentage">100</span>% owned subsidiaries, Mentor IP, LLC (“MCIP”), Mentor Partner I, LLC, (“Partner I”), Mentor Partner II, LLC (“Partner II”), and TWG, LLC (“TWG”), are headquartered in Plano, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MCIP holds intellectual property and licensing rights related to one United States and one Canadian patent associated with THC and CBD vape pens. Patent application and national phase maintenance fees were expensed when paid rather than capitalized and therefore, no capitalized assets related to MCIP are recognized on the consolidated financial statements at September 30, 2023 and December 31, 2022. Subsequent to quarter end, on October 24, 2023, MCIP divested its intellectual property and licensing rights related to the United States and the Canadian patents. See Note 20.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2021, the Company and Mentor Partner I entered into a Settlement Agreement and Mutual Release with the G Farma Entities and guarantors (“G Farma Settlors”) to resolve and settle all outstanding claims on an unpaid finance lease receivable and notes receivable of balances of $<span id="xdx_90E_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20210827__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember_z5oWwi3WzJV2" title="Finance lease receivable">803,399 </span>and $<span id="xdx_90C_eus-gaap--NotesReceivableGross_iI_c20210827__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember_zBbLv3eSloV3" title="Notes receivable">1,045,051</span>, respectively, plus accrued interest (“Settlement Agreement”). On October 12, 2021, the parties filed a Stipulation for Dismissal and Continued Jurisdiction with the Superior Court of California in the County of Marin. The Court ordered that it retain jurisdiction over the parties under Section 664.6 of the California Code of Civil Procedure to enforce the Settlement Agreement until the performance in full of its terms is met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, September 2022, and October 2022, the G Farma Settlors failed to make monthly payments, and failed to cure each default within 10 days’ notice from Company pursuant to the Settlement Agreement. In February 2023, the Company and Mentor Partner I filed a Request for Court Judgment requesting that the stipulated judgment agreed as part of the Settlement Agreement be entered against the G Farma Settlors for (1) the remaining amount of the $<span id="xdx_90E_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zt5WIXVvclkb" title="Liability for unpaid claims and claims adjustment expense, net"><span id="xdx_903_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zf5X1Qop35Tf" title="Liability for unpaid claims and claims adjustment expense, net"><span id="xdx_909_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z7V1cQcq79f5" title="Liability for unpaid claims and claims adjustment expense, net">500,000</span></span></span> settlement amount which has not yet been paid by the G Farma Settlors plus $<span id="xdx_90F_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zRFmEPoHx36e" title="Liability for accrued unpaid interest"><span id="xdx_903_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zp9A9FcgCa54" title="Liability for accrued unpaid interest"><span id="xdx_904_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zwst0acwDck1" title="Liability for accrued unpaid interest">2,000,000</span></span></span> and all accrued unpaid interest, (2) the Company’s incurred costs, and (3) attorneys’ fees paid by the Company to obtain the judgment. On July 11, 2023, the Court entered judgment against the G Farma Settlors and in favor of Mentor and Partner I in the amount of $<span id="xdx_903_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zmYW5MiMVZf9" title="Litigation settlement amount awarded from other party">2,539,597</span>, which is comprised of $<span id="xdx_90D_ecustom--LitigationSettlementDefaultAmount_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zM8zPACAgqpc" title="Litigation settlement default amount">2,494,450</span> of the default settlement amount (calculated as the settlement payment, less payments made by the G Farma Settlors, plus the default addition) plus accrued and unpaid interest of $<span id="xdx_909_eus-gaap--LitigationSettlementInterest_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zobygRngdIcf" title="Litigation settlement interest amount">40,219</span>, costs of $<span id="xdx_907_eus-gaap--LitigationSettlementExpense_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zUi9k6x9TSGb" title="Litigation settlement costs">1,643</span>, and attorneys’ fees of $<span id="xdx_90A_eus-gaap--LegalFees_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z3LIPYSV99A" title="Attorneys fee">3,285 </span>incurred by Mentor and Mentor Partner I in connection with obtaining the judgement. The judgment also accrues post-judgment interest at the rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_c20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z4d9QItrsII1" title="Debt instrument, interest rate, effective percentage">10%</span> from July 11, 2023 until such time as the judgment is paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained the full reserve on the unpaid notes receivable balance and collections of the unpaid lease receivable balance due to the long history of uncertain payments from G Farma and the G Farma Settlors. Payments from G Farma and G Farma Settlors will be recognized in Other Income as they are received. Recovery payments of $<span id="xdx_900_eus-gaap--OtherIncome_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_znGVQbqIeqz" title="Other income">3,550 </span>and $<span id="xdx_905_eus-gaap--OtherIncome_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zLvV9C3yKsmb" title="Other income">2,000 </span>were included in other income in the consolidated financial statements for the year ended December 31, 2022 and 2021, respectively. No recovery payments have received since October 11, 2022. The $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zeGU06nS1Obe" title="Litigation settlement amount awarded from other party">2,539,597</span> judgment and interest receivable of $<span id="xdx_900_eus-gaap--LitigationSettlementInterest_c20230701__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zasxk88wLor6" title="Interest receivable"><span id="xdx_905_eus-gaap--LitigationSettlementInterest_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zN1NNX0nSm4k" title="Interest receivable">56,358</span></span> for the three months and nine months ended September 30, 2023 is fully reserved pending the outcome of the Company’s collection process. See Notes 1, 8, and 18.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1 - Nature of operations (continued)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2022, Pueblo West Organics, LLC, a Colorado limited liability company (“Pueblo West”) exercised a lease prepayment option and purchased manufacturing equipment from Partner II for $<span id="xdx_909_eus-gaap--PaymentsToAcquireMachineryAndEquipment_pdp0_c20220927__20220927__dei--LegalEntityAxis__custom--PuebloWestOrganicsLLCMember_zOW2DSZVULqc" title="Payments to acquire machinery and equipment">245,369</span>. On September 28, 2022 Partner II transferred full title to the equipment to Pueblo West. Originally, Mentor contributed $<span id="xdx_904_eus-gaap--LimitedPartnersContributedCapital_iI_pp0p0_c20220928__dei--LegalEntityAxis__custom--MentorPartnerIILLCMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember_zKDFkmsoM07" title="Capital contribution">400,000</span> to Partner II to facilitate the purchase of manufacturing equipment to be leased from Partner II by Pueblo West under a Master Equipment Lease Agreement dated February 11, 2018, as amended. On March 12, 2019, Mentor agreed to use Partner II earnings of $<span id="xdx_90B_eus-gaap--PaymentsToAcquireMachineryAndEquipment_pp0p0_c20190312__20190312__dei--LegalEntityAxis__custom--MentorPartnerIILLCMember_zxk5TvTIBeb9" title="Payments to acquire machinery and equipment">61,368</span> to facilitate the purchase of additional manufacturing equipment to Pueblo West under a Second Amendment to the lease. See Note 8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2022, following the filing of a declaratory relief action, Mentor received $<span id="xdx_904_ecustom--ContractualInterestsInLegalRecoveriess_c20221118__20221118__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zbffudwyh23c" title="Contractual interests in legal recoveriess">459,990</span> from Electrum Partners, LLC (“Electrum”) pursuant to a certain November 14, 2022 Settlement Agreement and Mutual Release, following the Company’s October 21, 2022 lawsuit against Electrum and the escrow agent in the County of San Mateo. The Company applied $<span id="xdx_906_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--RecoveryPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_z5JjRR0BtBWb" title="Contractual interests in legal recoveries">196,666</span> to a certain October 30, 2018, Recovery Purchase Agreement, and $<span id="xdx_901_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--CapitalAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zJaMZmIOAcV2" title="Contractual interests in legal recoveries">200,000</span> to an October 31, 2018 and January 28, 2019 Capital Agreement. The Company applied the remaining $<span id="xdx_90A_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zHpeQyLkji5l" title="Contractual interests in legal recoveries">63,324</span> to its $<span id="xdx_909_ecustom--ContractualInterestEquityInterest_iI_c20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zKypnUXn0wrb" title="Contractual interest equity interest">194,028</span> equity interest in Electrum; this resulted in a $<span id="xdx_90C_eus-gaap--LossOnSaleOfInvestments_pp0p0_c20221118__20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zI5AJOgGg6M4" title="Loss on investment">130,704 </span>loss on the Company’s investment in Electrum. See Note 9.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 22, 2017 and October 31, 2018, the Company purchased convertible notes in principal face value of $<span id="xdx_901_ecustom--ConvertibleNotesReceivable_iI_c20171122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_z4keiSmPCMTe" title="Convertible note receivable">50,000</span> and $<span id="xdx_90F_ecustom--ConvertibleNotesReceivable_iI_c20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zypAyVGRtm9h" title="Convertible note receivable">25,000</span>, respectively, from NeuCourt, Inc. (“NeuCourt”) that each bore interest at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20171122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zvbe1wplreSi" title="Interest rate"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zB4DfmBWGjA" title="Interest rate">5</span></span>% per annum. On November 7, 2019, October 28, 2020, and January 4, 2022, the Company received <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191107__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zjoMbm7NEaPb" title="Warrants to purchase common stock">25,000</span>, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201028__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zdsRPGpO00N1" title="Warrants to purchase common stock">52,000</span>, and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zyYAJxNe81I1" title="Warrants to purchase common stock">27,630</span> warrants covering an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTIgCSKeymw6" title="Warrants to purchase common stock">105,130</span> shares of NeuCourt common stock exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrs41kk4Qnf6" title="Aggregate common stock, shares exercise price">0.02</span> per share in exchange for the Company’s agreement to extend the maturity dates of the convertible notes. On July 15, 2022, all principal and accrued interest on the notes were converted into a Simple Agreement for Future Equity (“SAFE”). At September 30, 2023, the SAFE Purchase Amount is $<span id="xdx_90A_ecustom--OutstandingAggregatePurchaseAmount_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquitySAFEMember_zkLpPUSFzCJb" title="Outstanding aggregate purchase amount">93,756</span>. See Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 21, 2018, Mentor paid $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20181201__20181221__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zjixrJzXfke" title="Stock issued, value">10,000</span> to purchase <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20181201__20181221__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_z0GrElMvpCul" title="Stock issued, shares">500,000</span> shares of NeuCourt common stock, representing approximately <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zJPLfUpkLVU9" title="Entity issued and outstanding common stock, percentage">6.13</span>% of NeuCourt’s issued and outstanding common stock at September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1994-07-29
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11697286 usd
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
116430 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
41930 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zfjYWji8zStb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zpNjyyydb5t6">Use of estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the reported amount of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2 - Summary of significant accounting policies (continued)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates relied upon in preparing these consolidated financial statements include revenue recognition, accounts and notes receivable reserves, expected future cash flows used to evaluate the recoverability of long-lived assets, estimated fair values of long-lived assets used to record impairment charges related to investments, goodwill, amortization periods, accrued expenses, and recoverability of the Company’s net deferred tax assets and any related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. Acquisitions and divestitures are not announced until certain. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
51959 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
53692 usd
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
116430 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
41930 usd
us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentImpairment_zTBq80bkvTw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zUfdh5FScGlg">Property and equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed on the declining balance method over the estimated useful lives of various classes of property. The estimated lives of the property and equipment are generally as follows: computer equipment, <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zuyj4CsdCqc5">3</span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zpQM0usdGbMj">5</span> years; furniture and equipment, <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zuQUYLxhNTa2">7</span> years; and vehicles and trailers, <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MinimumMember_zgZBBSYVUMa1">4</span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MaximumMember_zirRo6n2ItK4">5</span> years. Depreciation on vehicles used by WCI to service its customers is included in cost of goods sold in the consolidated income statements. All other depreciation is included in selling, general and administrative costs in the consolidated income statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for major renewals and improvements are capitalized, while minor replacements, maintenance, and repairs, which do not extend the asset lives, are charged to operations as incurred. Upon sale or disposition, the cost and related accumulated depreciation are removed from the accounts, and any gain or loss is included in operations. The Company continually monitors events and changes in circumstances that could indicate that the carrying balances of its property and equipment may not be recoverable in accordance with the provisions of ASC 360, <i>“Property, Plant, and Equipment.” </i>When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6700000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2022 MNTR Impairment Of Investments1
ImpairmentOfInvestments1
-139148 usd
CY2021 us-gaap Gain Loss On Investments
GainLossOnInvestments
22718 usd
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
-41930 usd
CY2021 us-gaap Gain Loss On Investments
GainLossOnInvestments
22718 usd
CY2023Q1 MNTR Purchase Obligation Due In Current Year
PurchaseObligationDueInCurrentYear
117000 usd
CY2023Q1 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
117000 usd
CY2023Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
117000 usd
CY2023Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
117000 usd
CY2023Q3 MNTR Investment In Account Receivable Face Value
InvestmentInAccountReceivableFaceValue
285700 usd
CY2022Q4 MNTR Investment In Account Receivable Face Value
InvestmentInAccountReceivableFaceValue
403600 usd
CY2023Q3 MNTR Investment In Account Receivable Unamortized Discount
InvestmentInAccountReceivableUnamortizedDiscount
61200 usd
CY2022Q4 MNTR Investment In Account Receivable Unamortized Discount
InvestmentInAccountReceivableUnamortizedDiscount
88291 usd
CY2023Q3 MNTR Investment In Account Receivable Net
InvestmentInAccountReceivableNet
224500 usd
CY2022Q4 MNTR Investment In Account Receivable Net
InvestmentInAccountReceivableNet
315309 usd
CY2023Q3 MNTR Investment In Account Receivable Noncurrent
InvestmentInAccountReceivableNoncurrent
224500 usd
CY2022Q4 MNTR Investment In Account Receivable Noncurrent
InvestmentInAccountReceivableNoncurrent
315309 usd
CY2023Q1 MNTR Purchase Obligation Due In Current Year
PurchaseObligationDueInCurrentYear
117000 usd
CY2023Q1 MNTR Investment In Accounts Receivable Face Value
InvestmentInAccountsReceivableFaceValue
117000 usd
CY2023Q3 MNTR Investment In Accounts Receivable Face Value
InvestmentInAccountsReceivableFaceValue
100 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10484 usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12916 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
27091 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
38754 usd
CY2023Q3 MNTR Sales Tax Receivable
SalesTaxReceivable
20374 usd
CY2022Q4 MNTR Sales Tax Receivable
SalesTaxReceivable
237243 usd
CY2022Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
6921 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
20374 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
230322 usd
CY2022 MNTR Employee Retention Credits
EmployeeRetentionCredits
1350161 usd
CY2022Q3 MNTR Employee Retention Income
EmployeeRetentionIncome
0 usd
MNTR Employee Retention Income
EmployeeRetentionIncome
1350161 usd
CY2022Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1272263 usd
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
77898 usd
CY2023Q3 MNTR Employee Retention Income
EmployeeRetentionIncome
0 usd
MNTR Employee Retention Income
EmployeeRetentionIncome
0 usd
CY2021Q4 MNTR Employee Retention Tax Credits As Refund
EmployeeRetentionTaxCreditsAsRefund
33222 usd
CY2022Q4 MNTR Employee Retention Tax Credits As Refund
EmployeeRetentionTaxCreditsAsRefund
0 usd
CY2023Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
33626 usd
CY2022Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
31335 usd
CY2023Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
27374 usd
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
27374 usd
CY2023Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
380077 usd
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
297016 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
441077 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
355725 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
259199 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
208847 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181878 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
146878 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
19181 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18207 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
50352 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
51847 usd
CY2022Q3 MNTR Operating Lease Cost Included In Cost Of Goods
OperatingLeaseCostIncludedInCostOfGoods
976 usd
MNTR Operating Lease Cost Included In Cost Of Goods
OperatingLeaseCostIncludedInCostOfGoods
16904 usd
CY2023Q3 MNTR Operating Lease Cost Included In Operating Costs
OperatingLeaseCostIncludedInOperatingCosts
18398 usd
CY2022Q3 MNTR Operating Lease Cost Included In Operating Costs
OperatingLeaseCostIncludedInOperatingCosts
7500 usd
MNTR Operating Lease Cost Included In Operating Costs
OperatingLeaseCostIncludedInOperatingCosts
60256 usd
MNTR Operating Lease Cost Included In Operating Costs
OperatingLeaseCostIncludedInOperatingCosts
22200 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18398 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
8476 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
60256 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
39104 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
104383 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
54855 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
269470 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
149687 usd
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
23394 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7258 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
56450 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
21116 usd
CY2023Q3 MNTR Financing Lease Cost
FinancingLeaseCost
127777 usd
CY2022Q3 MNTR Financing Lease Cost
FinancingLeaseCost
62113 usd
MNTR Financing Lease Cost
FinancingLeaseCost
325920 usd
MNTR Financing Lease Cost
FinancingLeaseCost
170803 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
146175 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
70589 usd
us-gaap Lease Cost
LeaseCost
386176 usd
us-gaap Lease Cost
LeaseCost
209907 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y5M26D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M17D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060 pure
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.075 pure
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.055 pure
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1696301 usd
CY2022Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
897849 usd
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
207418 usd
CY2022Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
89939 usd
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1488883 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
807910 usd
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
419073 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
232058 usd
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1069810 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
575852 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
366918 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
428946 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
43043 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
58782 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
323875 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
370164 usd
CY2023Q3 MNTR Operating Lease Liabilities Current
OperatingLeaseLiabilitiesCurrent
67804 usd
CY2022Q4 MNTR Operating Lease Liabilities Current
OperatingLeaseLiabilitiesCurrent
62861 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
256071 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
307303 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
419073 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
67804 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
424735 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
74860 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
388723 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
82475 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
251571 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
90670 usd
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
4781 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8066 usd
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1488883 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
323875 usd
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
419073 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67804 usd
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1069810 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
256071 usd
CY2023Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
1998-08-21
CY2023Q3 MNTR Warrant Redemption Price
WarrantRedemptionPrice
0.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P14Y9M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P15Y6M
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.11
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.11
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
CY2023Q3 MNTR Warrant Redemption Price
WarrantRedemptionPrice
0.10
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
300000 shares
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
255252 shares
CY2022 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
44748 shares
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
255252 shares
CY2022 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
44748 shares
CY2023Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
300000 shares
CY2023Q3 MNTR Stock Repurchase Program Average Price Paid Per Share
StockRepurchaseProgramAveragePricePaidPerShare
0.029
CY2023Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
300000 shares
CY2023Q3 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 MNTR Long Term Debt One
LongTermDebtOne
18427 usd
CY2022Q4 MNTR Long Term Debt Two
LongTermDebtTwo
44529 usd
CY2022Q4 MNTR Long Term Debt Three
LongTermDebtThree
20920 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
83876 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
29011 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
54865 usd
CY2023Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
58032 usd
CY2022Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
161060 usd
CY2023Q3 MNTR Accrued Salaries And Benefits
AccruedSalariesAndBenefits
938381 usd
CY2022Q4 MNTR Accrued Salaries And Benefits
AccruedSalariesAndBenefits
914072 usd
CY2023Q3 MNTR Accrued Retirement And Other Benefits
AccruedRetirementAndOtherBenefits
496425 usd
CY2022Q4 MNTR Accrued Retirement And Other Benefits
AccruedRetirementAndOtherBenefits
501529 usd
CY2023Q3 MNTR Offset By Shareholder Advance
OffsetByShareholderAdvance
-261653 usd
CY2022Q4 MNTR Offset By Shareholder Advance
OffsetByShareholderAdvance
-261653 usd
CY2023Q3 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1173153 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1153948 usd
CY2023Q3 MNTR Incentive Fee Percentage
IncentiveFeePercentage
0.01 pure
CY2023Q3 us-gaap Capitalization Longterm Debt And Equity
CapitalizationLongtermDebtAndEquity
260000 usd
CY2023Q3 MNTR Market Capitalization Rate
MarketCapitalizationRate
0.005 pure
us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1
us-gaap Incentive Fee Expense
IncentiveFeeExpense
0 usd
us-gaap Incentive Fee Expense
IncentiveFeeExpense
0 usd
us-gaap Loss Contingency Lawsuit Filing Date
LossContingencyLawsuitFilingDate
May 28, 2019
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q3 us-gaap Revenues
Revenues
2151811 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-192729 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
10730 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
29553 usd
CY2023Q3 MNTR Property Additions
PropertyAdditions
46763 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19181 usd
CY2022Q3 us-gaap Revenues
Revenues
1930299 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-422041 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12887 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
20283 usd
CY2022Q3 MNTR Property Additions
PropertyAdditions
18334 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18207 usd
us-gaap Revenues
Revenues
6432616 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-256428 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
27564 usd
us-gaap Interest Expense
InterestExpense
76349 usd
MNTR Property Additions
PropertyAdditions
85353 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50352 usd
CY2023Q3 us-gaap Assets
Assets
5169773 usd
us-gaap Revenues
Revenues
5647817 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1054428 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
40632 usd
us-gaap Interest Expense
InterestExpense
58052 usd
MNTR Property Additions
PropertyAdditions
46236 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51847 usd
CY2022Q3 us-gaap Assets
Assets
5841005 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-192729 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-422041 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-256428 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1054428 usd
MNTR Employee Retention Credits
EmployeeRetentionCredits
6921 usd
MNTR Employee Retention Credits
EmployeeRetentionCredits
1350161 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
939 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
590 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
715 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-39661 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
10730 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12887 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
27564 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
40632 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
29553 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
20283 usd
us-gaap Interest Expense
InterestExpense
76349 usd
us-gaap Interest Expense
InterestExpense
58052 usd
us-gaap Gain Loss On Sale Of Property
GainLossOnSaleOfProperty
56455 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1021 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56128 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14430 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58026 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-209592 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-372719 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-283147 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
353133 usd

Files In Submission

Name View Source Status
0001493152-23-040442-index-headers.html Edgar Link pending
0001493152-23-040442-index.html Edgar Link pending
0001493152-23-040442.txt Edgar Link pending
0001493152-23-040442-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex10-1_001.jpg Edgar Link pending
ex10-1_002.jpg Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mntr-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mntr-20230930_cal.xml Edgar Link unprocessable
mntr-20230930_def.xml Edgar Link unprocessable
mntr-20230930_lab.xml Edgar Link unprocessable
mntr-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending